Annovis Bio Inc. (ANVS): Price and Financial Metrics


Annovis Bio Inc. (ANVS)

Today's Latest Price: $5.48 USD

0.10 (1.86%)

Updated Nov 24 8:00pm

Add ANVS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ANVS Stock Price Chart Interactive Chart >

Price chart for ANVS

ANVS Price/Volume Stats

Current price $5.48 52-week high $10.61
Prev. close $5.38 52-week low $2.42
Day low $5.36 Volume 32,895
Day high $5.60 Avg. volume 300,765
50-day MA $4.95 Dividend yield N/A
200-day MA $4.74 Market Cap 37.77M

Annovis Bio Inc. (ANVS) Company Bio


Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.


ANVS Latest News Stream


Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream


Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about Annovis Bio Inc that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

Dosing underway in Annovis Bio's mid-stage Alzheimer’s and Parkinson’s trial

Annovis Bio (ANVS) announces dosing of the first three patients in its new Phase 2a clinical trial targeting early Alzheimer’s disease ((AD)) and Parkinson’s disease ((PD)). The two-part study is designed to treat a combined total of 28 AD and PD patients for four weeks with lead compound, ANVS401.The study...

Seeking Alpha | September 1, 2020

Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania

BERWYN, Pa., July 20, 2020 -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and.

Yahoo | July 20, 2020

Annovis Bio off highs on lead drug advancement-stoked rally

Thinly traded nano cap Annovis Bio ([[ANVS]] +77.3%) jumps on a whopping 506x surge in volume in reaction to its announcement that it has secured IRB approval to proceed with a 15-site clinical trial evaluating lead drug ANVS401 in Alzheimer's and Parkinson's patients.The stock was the top gainer in the...

Seeking Alpha | July 7, 2020

CRVS, HEPA Jump On COVID-19 Drug Bandwagon, LVGO In Good Health, NVAX Joins $100 Stock Price Club

Today's Daily Dose brings you news about the pipeline progress of Annovis Bio, new entrants in the COVID-19 drug development space, Livongo Health's upbeat preliminary Q2 revenue, Regeneron's BARDA contract, Novavax stock price touching new high and Mallinckrodt's near-term regulatory catalyst.

RTT News | July 7, 2020

Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients

Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it has received Central Institutional Review Board (IRB) approval to begin its Phase 2 clinical study in early PD and early AD patients at 15 sites across the US. An IRB is a committee that applies research ethics by reviewing the methods proposed for research to ensure that they are ethical. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in a research study.

Yahoo | July 7, 2020

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo 12.99%
3-mo 13.46%
6-mo 23.43%
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7778 seconds.